Clinical Trials Logo

Clinical Trial Summary

This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.

Clinical Trial Description

Eligible subjects will receive a single dose of radiolabeled AT-03, a fusion protein of serum amyloid P and a single chain Fc receptor. Repeat Positron Emission Tomography/Computed Tomography (PET/CT) scans will be performed over a ~7 day period to assess the biodistribution of AT-03 to amyloid-containing tissues in patients with systemic amyloidosis. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05201911
Study type Interventional
Source Attralus, Inc.
Status Completed
Phase Phase 1
Start date November 30, 2021
Completion date September 6, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05951049 - A Study of AT-02 in Subjects With Systemic Amyloidosis. Phase 2
Recruiting NCT05521022 - Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis Phase 1
Active, not recruiting NCT04474938 - Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis Phase 2
Terminated NCT02994784 - Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Phase 2
Recruiting NCT06192979 - Optimize First-line Treatment for AL Amyloidosis With t (11; 14) N/A
Completed NCT03401372 - BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients N/A